US2018186871A1PendingUtilityA1
Il-11 antibodies
Assignee: SINGAPORE HEALTH SERV PTE LTDPriority: Dec 16, 2016Filed: Dec 15, 2017Published: Jul 5, 2018
Est. expiryDec 16, 2036(~10.4 yrs left)· nominal 20-yr term from priority
C07K 2317/515A61P 11/00A61P 17/00C07K 2319/75C07K 2317/24C07K 14/7155A61P 35/00C07K 2317/33A61P 9/00A61K 2039/505C07K 2317/92C07K 2317/56C07K 2317/52A61P 1/16A61P 17/02A61K 47/6845C07K 2317/21C07K 16/244C07K 2317/565A61P 13/12C07K 2317/76A61P 27/02C07K 14/5431C07K 2317/622A61P 43/00C07K 2317/20G01N 2333/5431G01N 33/6869G01N 2800/52
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
IL-11 antibodies are disclosed. Also disclosed are compositions comprising the IL-11 antibodies, and methods using the IL-11 antibodies.
Claims
exact text as granted — not AI-modified1 - 99 . (canceled)
100 . An antibody or antigen binding fragment, optionally isolated, which is capable of binding to IL-11, comprising a light chain variable region sequence and a heavy chain variable region sequence, wherein:
the light chain variable region sequence has at least 85% sequence identity to the light chain variable region sequence of SEQ ID NO:342, and the heavy chain variable region sequence has at least 85% sequence identity to the heavy chain variable region sequence of SEQ ID NO:382.
101 . The antibody or antigen binding fragment according to claim 100 , wherein:
the light chain variable region sequence has at least 90% sequence identity to the light chain variable region sequence of SEQ ID NO:342, and the heavy chain variable region sequence has at least 90% sequence identity to the heavy chain variable region sequence of SEQ ID NO:382.
102 . The antibody or antigen binding fragment according to claim 100 , wherein the light chain variable region sequence comprises the following CDRs:
i) LC-CDR1:
(SEQ ID NO: 110)
SSDVGAYNY,
(SEQ ID NO: 107)
SSDVGGYNY
or
(SEQ ID NO: 330)
SSDVAGYNY;
ii) LC-CDR2:
(SEQ ID NO: 108)
DVS,
(SEQ ID NO: 291)
DVN
or
(SEQ ID NO: 123)
DVT;
and
iii) LC-CDR3:
(SEQ ID NO: 131)
CSYAGSYTWV
or
(SEQ ID NO: 336)
CSYAGRYTWM;
and wherein the heavy chain variable region sequence comprises the following CDRs
iv) HC-CDR1:
(SEQ ID NO: 190)
GFTFSSYA
or
(SEQ ID NO: 186)
GFTFSSYG;
v) HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
vi) HC-CDR3:
(SEQ ID NO: 199)
ARIMGYDYGDYDVVDY
or
(SEQ ID NO: 187)
AKIGATDPLDY.
103 . The antibody or antigen binding fragment according to claim 100 , wherein the light chain variable region sequence comprises the following CDRs:
i) LC-CDR1:
(SEQ ID NO: 110)
SSDVGAYNY;
ii) LC-CDR2:
(SEQ ID NO: 108)
DVS;
and
iii) LC-CDR3:
(SEQ ID NO: 131)
CSYAGSYTWV;
and wherein the heavy chain variable region sequence comprises the following CDRs
iv) HC-CDR1:
(SEQ ID NO: 190)
GFTFSSYA;
v) HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
vi) HC-CDR3:
(SEQ ID NO: 199)
ARIMGYDYGDYDVVDY.
104 . The antibody or antigen binding fragment according to claim 100 , wherein the light chain variable region sequence comprises the following CDRs:
i) LC-CDR1:
(SEQ ID NO: 107)
SSDVGGYNY;
ii) LC-CDR2:
(SEQ ID NO: 291)
DVN;
and
iii) LC-CDR3:
(SEQ ID NO: 336)
CSYAGRYTWM;
and wherein the heavy chain variable region sequence comprises the following CDRs
iv) HC-CDR1:
(SEQ ID NO: 186)
GFTFSSYG;
v) HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
vi) HC-CDR3:
(SEQ ID NO: 187)
AKIGATDPLDY.
105 . The antibody or antigen binding fragment according to claim 100 , wherein the light chain variable region sequence comprises the following CDRs:
i) LC-CDR1:
(SEQ ID NO: 330)
SSDVAGYNY;
ii) LC-CDR2:
(SEQ ID NO: 123)
DVT
and
iii) LC-CDR3:
(SEQ ID NO: 131)
CSYAGSYTWV;
and wherein the heavy chain variable region sequence comprises the following CDRs
iv) HC-CDR1:
(SEQ ID NO: 186)
GFTFSSYG;
v) HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
vi) HC-CDR3:
(SEQ ID NO: 187)
AKIGATDPLDY.
106 . The antibody or antigen binding fragment according to claim 100 , which is capable of inhibiting IL-11 trans signalling.
107 . The antibody or antigen binding fragment according claim 100 , conjugated to a drug moiety or a detectable moiety.
108 . A method of treating fibrosis or a disease/disorder characterised by fibrosis, comprising administering an antibody or antigen binding fragment to a subject suffering from fibrosis or a disease/disorder characterised by fibrosis, wherein the antibody or antigen binding fragment is capable of binding to IL-11, and comprises a light chain variable region sequence and a heavy chain variable region sequence, wherein:
the light chain variable region sequence has at least 85% sequence identity to the light chain variable region sequence of SEQ ID NO:342, and the heavy chain variable region sequence has at least 85% sequence identity to the heavy chain variable region sequence of SEQ ID NO:382.
109 . The method according to claim 108 , wherein:
the light chain variable region sequence has at least 90% sequence identity to the light chain variable region sequence of SEQ ID NO:342, and the heavy chain variable region sequence has at least 90% sequence identity to the heavy chain variable region sequence of SEQ ID NO:382.
110 . The method according to claim 108 , wherein the light chain variable region sequence comprises the following CDRs:
i) LC-CDR1:
(SEQ ID NO: 110)
SSDVGAYNY,
(SEQ ID NO: 107)
SSDVGGYNY
or
(SEQ ID NO: 330)
SSDVAGYNY;
ii) LC-CDR2:
(SEQ ID NO: 108)
DVS,
(SEQ ID NO: 291)
DVN
or
(SEQ ID NO: 123)
DVT;
and
iii) LC-CDR3:
(SEQ ID NO: 131)
CSYAGSYTWV
or
(SEQ ID NO: 336)
CSYAGRYTWM;
and wherein the heavy chain variable region sequence comprises the following CDRs
iv) HC-CDR1:
(SEQ ID NO: 190)
GFTFSSYA
or
(SEQ ID NO: 186)
GFTFSSYG;
v) HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
vi) HC-CDR3:
(SEQ ID NO: 199)
ARIMGYDYGDYDVVDY
or
(SEQ ID NO: 187)
AKIGATDPLDY.
111 . The method according to claim 108 , wherein the light chain variable region sequence comprises the following CDRs:
i) LC-CDR1:
(SEQ ID NO: 110)
SSDVGAYNY;
ii) LC-CDR2:
(SEQ ID NO: 108)
DVS;
and
iii) LC-CDR3:
(SEQ ID NO: 131)
CSYAGSYTWV;
and wherein the heavy chain variable region sequence comprises the following CDRs
iv) HC-CDR1:
(SEQ ID NO: 190)
GFTFSSYA;
v) HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
vi) HC-CDR3:
(SEQ ID NO: 199)
ARIMGYDYGDYDVVDY.
112 . The method according to claim 108 , wherein the light chain variable region sequence comprises the following CDRs:
i) LC-CDR1:
(SEQ ID NO: 107)
SSDVGGYNY;
ii) LC-CDR2:
(SEQ ID NO: 291)
DVN;
and
iii) LC-CDR3:
(SEQ ID NO: 336)
CSYAGRYTWM;
and wherein the heavy chain variable region sequence comprises the following CDRs
iv) HC-CDR1:
(SEQ ID NO: 186)
GFTFSSYG;
v) HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
vi) HC-CDR3:
(SEQ ID NO: 187)
AKIGATDPLDY.
113 . The method according to claim 108 , wherein the light chain variable region sequence comprises the following CDRs:
i) LC-CDR1:
(SEQ ID NO: 330)
SSDVAGYNY;
ii) LC-CDR2:
(SEQ ID NO: 123)
DVT;
and
iii) LC-CDR3:
(SEQ ID NO: 131)
CSYAGSYTWV;
and wherein the heavy chain variable region sequence comprises the following CDRs
iv) HC-CDR1:
(SEQ ID NO: 186)
GFTFSSYG;
v) HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
vi) HC-CDR3:
(SEQ ID NO: 187)
AKIGATDPLDY.
114 . A method of treating cancer, comprising administering an antibody or antigen binding fragment to a subject suffering from cancer, wherein the antibody or antigen binding fragment is capable of binding to IL-11, and comprises a light chain variable region sequence and a heavy chain variable region sequence, wherein:
the light chain variable region sequence has at least 85% sequence identity to the light chain variable region sequence of SEQ ID NO:342, and the heavy chain variable region sequence has at least 85% sequence identity to the heavy chain variable region sequence of SEQ ID NO:382.
115 . The method according to claim 114 , wherein:
the light chain variable region sequence has at least 90% sequence identity to the light chain variable region sequence of SEQ ID NO:342, and the heavy chain variable region sequence has at least 90% sequence identity to the heavy chain variable region sequence of SEQ ID NO:382.
116 . The method according to claim 114 , wherein the light chain variable region sequence comprises the following CDRs:
i) LC-CDR1:
(SEQ ID NO: 110)
SSDVGAYNY,
(SEQ ID NO: 107)
SSDVGGYNY
or
(SEQ ID NO: 330)
SSDVAGYNY;
ii) LC-CDR2:
(SEQ ID NO: 108)
DVS,
(SEQ ID NO: 291)
DVN
or
(SEQ ID NO: 123)
DVT;
and
iii) LC-CDR3:
(SEQ ID NO: 131)
CSYAGSYTWV
or
(SEQ ID NO: 336)
CSYAGRYTWM;
and wherein the heavy chain variable region sequence comprises the following CDRs
iv) HC-CDR1:
(SEQ ID NO: 190)
GFTFSSYA
or
(SEQ ID NO: 186)
GFTFSSYG;
v) HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
vi) HC-CDR3:
(SEQ ID NO: 199)
ARIMGYDYGDYDVVDY
or
(SEQ ID NO: 187)
AKIGATDPLDY.
117 . The method according to claim 114 , wherein the light chain variable region sequence comprises the following CDRs:
i) LC-CDR1:
(SEQ ID NO: 110)
SSDVGAYNY;
ii) LC-CDR2:
(SEQ ID NO: 108)
DVS;
and
iii) LC-CDR3:
(SEQ ID NO: 131)
CSYAGSYTWV;
and wherein the heavy chain variable region sequence comprises the following CDRs
iv) HC-CDR1:
(SEQ ID NO: 190)
GFTFSSYA;
v) HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
vi) HC-CDR3:
(SEQ ID NO: 199)
ARIMGYDYGDYDVVDY.
118 . The method according to claim 114 , wherein the light chain variable region sequence comprises the following CDRs:
i) LC-CDR1:
(SEQ ID NO: 107)
SSDVGGYNY;
ii) LC-CDR2:
(SEQ ID NO: 291)
DVN;
and
iii) LC-CDR3:
(SEQ ID NO: 336)
CSYAGRYTWM;
and wherein the heavy chain variable region sequence comprises the following CDRs
iv) HC-CDR1:
(SEQ ID NO: 186)
GFTFSSYG;
v) HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
vi) HC-CDR3:
(SEQ ID NO: 187)
AKIGATDPLDY.
119 . The method according to claim 114 , wherein the light chain variable region sequence comprises the following CDRs:
i) LC-CDR1:
(SEQ ID NO: 330)
SSDVAGYNY;
ii) LC-CDR2:
(SEQ ID NO: 123)
DVT;
and
iii) LC-CDR3:
(SEQ ID NO: 131)
CSYAGSYTWV;
and wherein the heavy chain variable region sequence comprises the following CDRs
iv) HC-CDR1:
(SEQ ID NO: 186)
GFTFSSYG;
v) HC-CDR2:
(SEQ ID NO: 184)
ISYDGSNK;
and
vi) HC-CDR3:
(SEQ ID NO: 187)
AKIGATDPLDY.Join the waitlist — get patent alerts
Track US2018186871A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.